.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,670,675

« Back to Dashboard

Details for Patent: 5,670,675

Title: Retroviral protease inhibiting compounds
Abstract:A retroviral protease inhibiting compound of the formula A-X-B or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein X is a linking group; A is (1) substituted amino, (2) substituted carbonyl, (3) functionalized imino, (4) functionalized alkyl, (5) functionalized acyl, (6) functionalized heterocyclic or (7) functionalized (heterocyclic)alkyl; and B is (1) substituted carbonyl independently defined as herein, (2) substituted amino independently defined as herein, (3) functionalized imino independently defined as herein, (4) functionalized alkyl independently defined as herein, (5) functionalized acyl independently defined as herein, (6) functionalized heterocyclic independently defined as herein or (7) functionalized (heterocyclic)alkyl independently defined as herein.
Inventor(s): Kempf; Dale J. (Lake Villa, IL), Norbeck; Daniel W. (Lindenhurst, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Filing Date:Mar 23, 1995
Application Number:08/409,365
Claims:1. A compound of the formula: ##STR525## wherein at each occurrence R.sub.3 is independently selected from the group consisting of

(i) C.sub.1 -to-C.sub.6 -loweralkyl,

(ii) aryl,

(iii) (aryl)-C.sub.1 -to-C.sub.6 -alkyl,

(iv) C.sub.3 -to-C.sub.7 -cycloalkyl and

(v) C.sub.3 -to-C.sub.7 -cycloalkyl-C.sub.1 -to-C.sub.6 -alkyl

R.sub.9 is independently selected at each occurrence from the group consisting of hydrogen and aryl-C.sub.1 -to-C.sub.6 -alkyl;

R.sub.17 at each occurrence is independently selected from the group consisting of C.sub.1 -to-C.sub.6 -loweralkyl, aryl and aryl-C.sub.1 -to-C.sub.6 -alkyl;

R.sub.800 is --O--;

and at each occurrence h is independently selected from the group consisting of 0 and 1;

wherein at each occurrence aryl is independently selected from phenyl, naphthyl, tetrahydronaphthyl, indanyl, tetrafluorophenyl and pentafluorophenyl and wherein the phenyl, naphthyl, tetrahydronaphthyl and indanyl rings are unsubstituted or substituted with one, two or three substitutents independently selected from the group consisting of C.sub.1 -to-C.sub.6 -loweralkyl, halo-C.sub.1 -to-C.sub.6 -alkyl, C.sub.1 -to-C.sub.6 -alkoxy, C.sub.1 -to-C.sub.6 -thioalkoxy, amino, C.sub.1 -to-C.sub.6 -alkylamino, di-C.sub.1 -to-C.sub.6 -alkylamino, hydroxy, halo, mercapto, nitro, carboxaldehyde, carboxy, carbo-C.sub.1 -to-C.sub.6 -alkoxy and carboxamide;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 of the formula: ##STR526## wherein at each occurrence R.sub.3 is independently selected from the group consisting of

C.sub.1 -to-C.sub.6 -loweralkyl, C.sub.3 -to-C.sub.7 -cycloalkyl, C.sub.3 -to-C.sub.7 -cycloalkyl-C.sub.1 -to-C.sub.6 -alkyl, aryl and aryl-C.sub.1 -to-C.sub.6 -alkyl;

R.sub.9 is independently selected at each occurrence from the group consisting of hydrogen and aryl-C.sub.1 -to-C.sub.6 -alkyl;

R.sub.17 at each occurrence is independently selected from the group consisting of C.sub.1 -to-C.sub.6 -loweralkyl, aryl and aryl-C.sub.1 -to-C.sub.6 -alkyl;

R.sub.800 is --O--;

and at each occurrence h is independently selected from the group consisting of 0 and 1;

or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 of the formula: ##STR527## wherein at each occurrence R.sub.3 is independently selected from the group consisting of

aryl-C.sub.1 -to-C.sub.6 -alkyl;

R.sub.9 is independently selected at each occurrence from the group consisting of hydrogen and aryl-C.sub.1 -to-C.sub.6 -alkyl;

R.sub.17 at each occurrence is independently selected from the group consisting of C.sub.1 -to-C.sub.6 -loweralkyl, aryl and arylC.sub.1 -to-C.sub.6 -alkyl;

R.sub.800 is --O--;

and at each occurrence h is independently selected from the group consisting of 0 and 1;

or a pharmaceutically acceptable salt thereof.

4. A compound selected from the group consisting of:

2-(N-benzyl-N-(benzyloxycarbonyl)amino)-5-(t-butyloxycarbonylamino)-1,6-dip henyl-3-hexene-3,4-oxide;

2-amino-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; and

2,5-di-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc